Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in RGS?
Regeneus Ltd: THE INVESTMENT CASE

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: RGS The Big Picture
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.
 

ACCESS THE FULL PRESENTATION HERE





Register here to be notified of future RGS Company articles
View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Paul Rennie talked timeline to clinical trial results with investors.
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use